Firebrick Pharma (ASX:FRE) - Executive Chairman, Dr Peter Molloy
Executive Chairman, Dr Peter Molloy
Source: Peter Molloy/LinkedIn
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Firebrick Pharma (FRE) recruits the first patient under its phase three trial for its Nasodine Nasal Spray as a treatment for the common cold
  • The trial will recruit up to 450 adult participants with early cold symptoms to achieve a target treatment population of 196 subjects
  • The primary endpoint will be the impact of Nasodine on overall cold severity which will be measured using the Global Severity Score from the WURSS-21 cold severity survey
  • Firebrick currently has two major clinical trials underway with results expected later in the year
  • Firebrick ends the day 1.23 per cent in the red with shares trading at 40 cents

Firebrick Pharma (FRE) has recruited the first patient under its phase three trial for its Nasodine Nasal Spray as a treatment for the common cold.

The trial will recruit up to 450 adult participants with early cold symptoms to achieve a target treatment population of 196 subjects.

It will be double-blinded, randomised and placebo-controlled, titled “Confirmatory Phase III study of Nasodine Nasal Spray (povidone-iodine 0.5 per cent) as a symptomatic treatment for early stage common cold in the natural setting.”

The primary endpoint will be the impact of Nasodine on overall cold severity, which will be measured using the Global Severity Score from the WURSS-21 cold severity survey.

The trial will be undertaken at three sites across Australia and two in South Africa with patients already recruited in Adelaide.

Firebrick currently has two major clinical trials underway with results expected later in the year.

“This is the second Phase 3 trial for Nasodine and we are excited to take what we believe will be the final step towards commercialisation of Nasodine in Australia, and to lay the pathway for international approval and distribution,” Executive Chairman Dr Peter Molloy said.

“Nasodine is a first-in-class nasal spray medicine that actually targets the viral cause of the common cold, where colds start — in the nose.”

Firebrick has ended the day 1.23 per cent in the red with shares trading at 40 cents.

FRE by the numbers
More From The Market Herald
Step One (ASX:STP)- Founder & CEO, Greg Taylor

" Step One Clothing (ASX:STP) shares plummet on slashed revenue and earnings guidance

Shares in Step One Clothing (ASX:STP) have nosedived after the company slashed revenue growth and earnings…
BHP Group (ASX:BHP) - CEO, Mike Henry

" BHP (ASX:BHP) to pay record interim dividend after strong half yearly results

BHP (ASX:BHP) will pay a record interim dividend of US$1.50 (A$2.10) after reporting a strong financial…
Kingfisher Mining (ASX:KFM) - CEO & Executive Director, James Farrell

" Kingfisher Mining (ASX:KFM) completes drilling in WA

Kingfisher Mining (ASX:KFM) has completed drilling at two of its projects in the Gascoyne Mineral Field…

" Ardea Resources (ASX:ARL) confirms nickel-cobalt mineralisation at Goongarrie South

Ardea Resources (ASX:ARL) has confirmed high-grade, near-surface nickel-cobalt mineralisation at the Goongarrie South deposit in WA.